

Michael P Lux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3727290/publications.pdf>

Version: 2024-02-01

104
papers

5,892
citations

117453

34
h-index

79541

73
g-index

117
all docs

117
docs citations

117
times ranked

9918
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world multi-country study of <i>BRCA1/2</i> mutation testing among adult women with HER2-negative advanced breast cancer. <i>Future Oncology</i> , 2022, 18, 1089-1101.	1.1	3
2	Update Breast Cancer 2021 Part 4 "Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2022, 82, 206-214.	0.8	4
3	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics " A retrospective analysis of a real world registry. <i>European Journal of Cancer</i> , 2022, 172, 13-21.	1.3	1
4	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Breast Care</i> , 2021, 16, 254-262.	0.8	0
5	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. <i>Breast Care</i> , 2021, 16, 291-298.	0.8	2
6	Macromastia: an economic burden? A disease cost analysis based on real-world data in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 521-531.	0.8	13
7	Is Reduction Mammoplasty Cost-Effective? A Cost-Utility Analysis of Surgical Treatment for Macromastia in Germany. <i>Breast Care</i> , 2021, 16, 1-9.	0.8	0
8	Mutations in <i>BRCA1/2</i> and Other Panel Genes in Patients With Metastatic Breast Cancer " Association With Patient and Disease Characteristics and Effect on Prognosis. <i>Journal of Clinical Oncology</i> , 2021, 39, 1619-1630.	0.8	39
9	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	1.3	39
10	The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?. <i>Cancer Management and Research</i> , 2021, Volume 13, 8457-8471.	0.9	10
11	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer " Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. <i>Breast</i> , 2020, 54, 88-95.	0.9	34
12	Biosimilars in oncology: Effects on economy and therapeutic innovations. <i>European Journal of Cancer</i> , 2020, 139, 10-19.	1.3	19
13	Update Breast Cancer 2019 Part 4 " Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1079-1089.	0.8	18
14	Update Breast Cancer 2019 Part 5 " Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 1090-1099.	0.8	16
15	Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy. <i>European Journal of Medical Research</i> , 2019, 24, 32.	0.9	6
16	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 224-245.	0.8	72
17	Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 495-506.	1.1	7
18	Can a University Reproductive Medicine Centre Be Financed Under the Pre-Existing General Conditions in Germany?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 63-71.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 617-625.	1.1	35
20	Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. <i>Breast Care</i> , 2019, 14, 41-47.	0.8	5
21	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	1.7	43
22	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461.	1.1	15
23	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 319-328.	1.1	40
24	An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 Breast Cancer: Reliability Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e10004.	2.1	29
25	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. <i>Breast Care</i> , 2018, 13, 8-14.	0.8	32
26	Update Breast Cancer 2018 (Part 1) â€œ Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	0.8	20
27	Filtration based assessment of CTCs and CellSearchÂ® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 204.	1.1	30
28	Update Breast Cancer 2018 (Part 2) â€œ Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	0.8	23
29	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors â€œ Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	0.9	54
30	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	0.9	56
31	Update Breast Cancer 2018 (Part 4) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1119-1128.	0.8	3
32	Update Breast Cancer 2018 (Part 3) â€œ Genomics, Individualized Medicine and Immune Therapies â€œ in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1110-1118.	0.8	8
33	Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. <i>BMC Cancer</i> , 2018, 18, 926.	1.1	16
34	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 1051.	1.1	59
35	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients â€œ a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 707-714.	0.8	3
36	Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer. <i>Breast</i> , 2017, 32, 186-191.	0.9	24

#	ARTICLE	IF	CITATIONS
37	Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network. Archives of Gynecology and Obstetrics, 2017, 295, 1239-1245.	0.8	42
38	A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO). Journal of Cancer Research and Clinical Oncology, 2017, 143, 541-550.	1.2	16
39	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
40	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. Geburtshilfe Und Frauenheilkunde, 2017, 77, 870-878.	0.8	24
41	Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. International Journal of Cancer, 2017, 140, 95-102.	2.3	99
42	Update Breast Cancer 2017 – Implementation of Novel Therapies. Geburtshilfe Und Frauenheilkunde, 2017, 77, 1281-1290.	0.8	19
43	Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity. Oncotarget, 2017, 8, 78133-78143.	0.8	6
44	Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients. JMIR Cancer, 2017, 3, e11.	0.9	38
45	Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial. Journal of Medical Internet Research, 2017, 19, e322.	2.1	48
46	The PI3K Pathway: Background and Treatment Approaches. Breast Care, 2016, 11, 398-404.	0.8	28
47	Chylous ascites after lymphadenectomy for gynecological malignancies. Journal of Surgical Oncology, 2016, 114, 613-618.	0.8	11
48	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. International Journal of Cancer, 2016, 139, 1967-1974.	2.3	19
49	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. Breast Cancer Research and Treatment, 2016, 158, 59-65.	1.1	27
50	Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. Archives of Gynecology and Obstetrics, 2016, 294, 343-351.	0.8	21
51	Association of molecular subtypes with breast cancer risk factors. European Journal of Cancer Prevention, 2015, 24, 484-490.	0.6	14
52	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. BMC Cancer, 2015, 15, 587.	1.1	19
53	Highlights from the Annual Meeting of the American Society of Clinical Oncology 2014 in Chicago - Expert Opinions Revisited. Breast Care, 2014, 9, 287-291.	0.8	0
54	Best Supportive Care from the Conservative/Non-Surgical Perspective and Its Costs in the Treatment of Patients with Advanced Medullary Thyroid Cancer: Results of a Delphi Panel. Oncology Research and Treatment, 2014, 37, 316-322.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Polymorphisms in the RANK/RANKL Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	18
56	FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients. <i>BMC Cancer</i> , 2014, 14, 66.	1.1	19
57	Comprehensive visualization of paresthesia in breast cancer survivors. <i>Archives of Gynecology and Obstetrics</i> , 2014, 290, 135-141.	0.8	11
58	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014, 35, 1012-1019.	1.3	145
59	Financing of certified centers: a willingness-to-pay analysis. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 495-509.	0.8	11
60	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060.	2.6	98
61	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
62	Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 429-440.	1.1	29
63	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 899-908.	1.1	23
64	Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 337-344.	0.8	13
65	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	9.4	374
66	Health Economics in Breast Cancer. <i>Breast Care</i> , 2013, 8, 5-6.	0.8	1
67	Economic Constraints - the Growing Challenge for Western Breast Cancer Centers. <i>Breast Care</i> , 2013, 8, 41-47.	0.8	4
68	Factors influencing breast changes after pregnancy. <i>European Journal of Cancer Prevention</i> , 2013, 22, 259-261.	0.6	9
69	Hormone replacement therapy and prognosis in ovarian cancer patients. <i>European Journal of Cancer Prevention</i> , 2013, 22, 52-58.	0.6	28
70	Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. <i>PLoS ONE</i> , 2012, 7, e29770.	1.1	219
71	Extent of Primary Breast Cancer Surgery: Standards and Individualized Concepts. <i>Breast Care</i> , 2012, 7, 364-369.	0.8	11
72	Characterizing mammographic images by using generic texture features. <i>Breast Cancer Research</i> , 2012, 14, R59.	2.2	65

#	ARTICLE	IF	CITATIONS
73	Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physicians. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 811-820.	1.1	19
74	Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 885-892.	1.1	36
75	Genome-wide association analysis identifies three new breast cancer susceptibility loci. <i>Nature Genetics</i> , 2012, 44, 312-318.	9.4	256
76	Association of mammographic density with hormone receptors in invasive breast cancers: Results from a case-only study. <i>International Journal of Cancer</i> , 2012, 131, 2643-2649.	2.3	44
77	Akt and p53 are potential mediators of reduced mammary tumor growth by Chloroquine and the mTOR inhibitor RAD001. <i>Biochemical Pharmacology</i> , 2012, 83, 480-488.	2.0	39
78	The Hohl instrument for optimizing total laparoscopic hysterectomy: results of more than 500 procedures in a university training center. <i>Archives of Gynecology and Obstetrics</i> , 2012, 285, 123-127.	0.8	31
79	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. <i>BMC Cancer</i> , 2011, 11, 486.	1.1	260
80	Diabetes and prognosis in a breast cancer cohort. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 975-983.	1.2	59
81	The era of centers: the influence of establishing specialized centers on patients' choice of hospital. <i>Archives of Gynecology and Obstetrics</i> , 2011, 283, 559-568.	0.8	43
82	Quality Assured Health Care in Certified Breast Centers and Improvement of the Prognosis of Breast Cancer Patients. <i>Onkologie</i> , 2011, 34, 362-367.	1.1	106
83	The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2141-2149.	1.1	6
84	Assessment of mammographic density before and after first full-term pregnancy. <i>European Journal of Cancer Prevention</i> , 2010, 19, 405-412.	0.6	21
85	Pain perception and detailed visual pain mapping in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 105-110.	1.1	24
86	Two different sides of "chemobrain": determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. <i>Psycho-Oncology</i> , 2010, 19, 1321-1328.	1.0	110
87	Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System. <i>Onkologie</i> , 2010, 33, 155-166.	1.1	18
88	Mitomycin C in Patients with Gynecological Malignancies. <i>Oncology Research and Treatment</i> , 2010, 33, 547-557.	0.8	7
89	Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study. <i>Onkologie</i> , 2010, 33, 360-368.	1.1	9
90	Are Certified Breast Centers Cost-Effective?. <i>Breast Care</i> , 2009, 4, 245-250.	0.8	27

#	ARTICLE	IF	CITATIONS
91	Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. <i>Breast</i> , 2009, 18, 135-141.	0.9	76
92	Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 305-317.	1.1	24
93	Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 89-98.	1.1	77
94	Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients. <i>Cancer</i> , 2008, 113, 2431-2439.	2.0	83
95	Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients. <i>Breast</i> , 2008, 17, 640-645.	0.9	16
96	Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. <i>European Journal of Cancer Prevention</i> , 2007, 16, 216-224.	0.6	27
97	Clinical and Preclinical Experience with Gefitinib and Sunitinib. <i>Breast Care</i> , 2007, 2, 68-73.	0.8	2
98	Cognitive function during neoadjuvant chemotherapy for breast cancer. <i>Cancer</i> , 2007, 109, 1905-1913.	2.0	316
99	The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugs. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 95-104.	1.1	18
100	Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics. <i>European Journal of Radiology</i> , 2006, 60, 398-404.	1.2	71
101	Acceptance for preventive genetic testing and prophylactic surgery in women with a family history of breast and gynaecological cancers. <i>European Journal of Cancer Prevention</i> , 2006, 15, 474-479.	0.6	7
102	Hereditary breast and ovarian cancer: review and future perspectives. <i>Journal of Molecular Medicine</i> , 2006, 84, 16-28.	1.7	149
103	Fulvestrant: A Further Treatment Option for Patients with Metastatic Uterine Cancer?. <i>Oncology Research and Treatment</i> , 2006, 29, 577-580.	0.8	6
104	Age of uptake of early cancer detection facilities by low-risk and high-risk patients with familial breast and ovarian cancer. <i>European Journal of Cancer Prevention</i> , 2005, 14, 503-511.	0.6	12